This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera/Rituxan (rituximab) in patients with severe active rheumatoid arthritis, who have an inadequate response to one or more anti-TNF therapies. Data will be collected for 12 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01613027?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
